HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuomi Kario Selected Research

Aldosterone

8/2022Sex-specific Association of Primary Aldosteronism With Visceral Adiposity.
1/2022Who should be screened for primary aldosteronism? A comprehensive review of current evidence.
1/2022Role of α1-blockers in the current management of hypertension.
1/2014An adverse pregnancy-associated outcome due to overlooked primary aldosteronism.
6/2008Increased low-grade inflammation and plasminogen-activator inhibitor-1 level in nondippers with sleep apnea syndrome.
1/2007Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuomi Kario Research Topics

Disease

209Hypertension (High Blood Pressure)
04/2024 - 05/2002
67Stroke (Strokes)
12/2023 - 01/2002
44Cardiovascular Diseases (Cardiovascular Disease)
11/2023 - 10/2002
30Heart Failure
12/2023 - 07/2008
18Essential Hypertension
01/2023 - 05/2002
17Atrial Fibrillation
12/2023 - 01/2011
17Masked Hypertension
01/2023 - 04/2007
16Type 2 Diabetes Mellitus (MODY)
11/2023 - 04/2004
16Diabetes Mellitus
01/2023 - 10/2004
14Coronary Artery Disease (Coronary Atherosclerosis)
11/2023 - 11/2009
13Cerebral Hemorrhage
12/2015 - 09/2009
12Myocardial Infarction
01/2023 - 01/2010
11Chronic Renal Insufficiency
01/2023 - 04/2007
11Atherosclerosis
04/2022 - 10/2004
10Obesity
10/2023 - 06/2008
10Body Weight (Weight, Body)
09/2023 - 05/2010
10Sleep Apnea Syndromes (Sleep Apnea)
01/2022 - 09/2006
10Inflammation (Inflammations)
01/2016 - 03/2007
9Hyperuricemia
04/2022 - 11/2019
9Hypoxia (Hypoxemia)
01/2021 - 11/2005
9Ischemic Stroke
01/2020 - 02/2004
9Cerebral Infarction
06/2012 - 10/2003
8Obstructive Sleep Apnea
03/2024 - 01/2016
8Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
10/2023 - 10/2004
8Acute Coronary Syndrome
11/2021 - 01/2005
8White Coat Hypertension
01/2020 - 01/2007
7Intracranial Hemorrhages (Intracranial Hemorrhage)
12/2023 - 04/2010
6Hemorrhage
12/2023 - 03/2014
6COVID-19
04/2023 - 01/2020
6Thrombosis (Thrombus)
01/2023 - 04/2017
6Apnea
01/2022 - 09/2006
6Cognitive Dysfunction
11/2018 - 07/2008
6Isolated Systolic Hypertension
01/2018 - 01/2015
5Carotid Artery Diseases
11/2023 - 01/2012
5Tachycardia (Tachyarrhythmias)
01/2020 - 12/2005
5Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2019 - 05/2007
5Cerebrovascular Disorders (Cerebrovascular Occlusion)
11/2018 - 07/2002
5Insulin Resistance
07/2011 - 01/2007
4Cardiac Arrhythmias (Arrythmia)
11/2020 - 07/2010
4Dementia (Dementias)
01/2020 - 02/2010
4Hyperlipidemias (Hyperlipidemia)
01/2019 - 10/2004
4Transient Ischemic Attack
01/2019 - 08/2015
4Albuminuria
11/2013 - 06/2006

Drug/Important Bio-Agent (IBA)

90Antihypertensive Agents (Antihypertensives)IBA
02/2024 - 01/2002
25SaltsIBA
09/2023 - 11/2008
18Biomarkers (Surrogate Marker)IBA
10/2023 - 01/2007
174- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA
01/2023 - 05/2015
15salicylhydroxamic acid (SHAM)IBA
04/2024 - 01/2016
14Brain Natriuretic Peptide (Natrecor)FDA Link
12/2023 - 01/2008
14Angiotensin Receptor AntagonistsIBA
11/2023 - 04/2009
14Glucose (Dextrose)FDA LinkGeneric
10/2023 - 01/2007
13olmesartanIBA
01/2023 - 04/2011
12DiureticsIBA
11/2023 - 06/2010
12Neprilysin (Neutral Endopeptidase)IBA
11/2023 - 02/2014
12Tissue Plasminogen Activator (Alteplase)FDA Link
10/2013 - 06/2008
12C-Reactive ProteinIBA
06/2013 - 03/2007
11omega-Chloroacetophenone (Mace)IBA
12/2023 - 01/2012
11Angiotensin Receptors (Angiotensin II Receptor)IBA
11/2023 - 02/2014
11sacubitril and valsartan sodium hydrate drug combinationIBA
01/2023 - 02/2014
11Amlodipine (Norvasc)FDA LinkGeneric
01/2018 - 05/2002
9AnticoagulantsIBA
12/2023 - 01/2012
9Warfarin (Coumadin)FDA LinkGeneric
12/2023 - 01/2012
9Sodium-Glucose Transporter 2 InhibitorsIBA
11/2023 - 01/2016
9pro-brain natriuretic peptide (1-76)IBA
10/2023 - 05/2014
9Uric Acid (Urate)IBA
02/2023 - 03/2017
8Oxygen (Dioxygen)IBA
01/2022 - 11/2005
8AlbuminsIBA
01/2022 - 06/2008
8CreatinineIBA
01/2022 - 08/2010
8cilnidipineIBA
01/2021 - 12/2005
7Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2023 - 05/2002
7Valsartan (Vals)FDA Link
01/2021 - 05/2007
7CalciumIBA
01/2021 - 05/2002
6Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
11/2023 - 05/2002
6Sodium-Glucose Transport ProteinsIBA
11/2023 - 01/2018
6AldosteroneIBA
08/2022 - 01/2007
6FebuxostatFDA Link
04/2022 - 01/2020
6CholesterolIBA
01/2022 - 06/2006
6SodiumIBA
01/2022 - 08/2008
6Doxazosin (Cardura)FDA LinkGeneric
01/2017 - 08/2004
6Indicators and Reagents (Reagents)IBA
01/2016 - 10/2003
5antineoplaston A10 (A 10)IBA
09/2023 - 12/2003
5Norepinephrine (Noradrenaline)FDA LinkGeneric
01/2016 - 06/2002
5Hemostatics (Antihemorrhagics)IBA
04/2015 - 10/2004
5azelnidipineIBA
03/2013 - 06/2007
4Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2023 - 04/2010
4Troponin T (Troponin T1)IBA
10/2023 - 05/2013
4esaxerenoneIBA
01/2023 - 01/2021
4LipidsIBA
01/2022 - 01/2007
4N-Type Calcium Channels (N-Type Calcium Channel)IBA
01/2021 - 12/2005
4candesartanIBA
06/2014 - 10/2002
4Adrenergic Agents (Adrenergic Drugs)IBA
12/2013 - 07/2002
4Insulin (Novolin)FDA Link
06/2010 - 06/2006

Therapy/Procedure

76Therapeutics
12/2023 - 09/2002
42Denervation
02/2024 - 06/2013
13Catheters
04/2024 - 01/2016
13Percutaneous Coronary Intervention
12/2023 - 01/2012
8Drug Therapy (Chemotherapy)
11/2023 - 09/2011
6Stents
04/2021 - 01/2012
4Sympathectomy (Sympathectomies)
04/2024 - 04/2019
4Continuous Positive Airway Pressure
01/2022 - 07/2014